VRBPAC endorsed mRNA-1010 for adults 50-64 and ≥65 years, unanimously concluding benefits outweighed risks, supporting a late-stage regulatory path toward potential first mRNA seasonal influenza ...
The vaccine, intended for people 50 and older, is based on mRNA technology and was found in an advanced trial to be more ...
The efficacy of flu shots is not always the same and it’s not always optimal. Some years, they can reduce the risk of illness by as little as 20% to 30%. Messenger RNA technology, or mRNA, is widely ...
A new kind of flu vaccine is moving a step closer to the U.S. market.
Influenza is a seasonal condition that causes coughing, sneezing, mild fever and aches in most cases. However, it can sometimes take a serious turn, leading to hospitalization, especially for young ...
The Pentagon said Wednesday that boot camps for all the military services are once again requiring the flu vaccination for ...
The efficacy of flu shots is not always the same and it’s not always optimal. Some years, they can reduce the risk of illness by as little as 20% to 30%. Subscribe to read this story ad-free Get ...